PEspeaks

Mar 29, 2015
A controversial FDA proposal to alter the process for making changes to approved drug labels has drawn opposition and support in equal measure, writes Jill Wechsler.
Mar 24, 2015
Albert Wertheimer, PhD, MBA, Professor of Pharmaceutical Economics at Temple University and a member of Pharm Exec's Editorial Advisory Board, shows how the simple matter of a drug shortage is not a simple matter at all.
Mar 21, 2015
PharmExec talks to babylon founder and CEO Ali Parsa on how technology will deliver healthcare services to patients globally.
Mar 17, 2015
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric — combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora
Mar 15, 2015
The Securities and Exchange Commission (SEC) is focusing more on the accuracy and timeliness of biopharma company financial filings, particularly those related to regulatory actions involving FDA, writes Jill Wechsler.
Mar 15, 2015
The EU’s proposed new study on off-label prescribing is just another way of kicking the issue into the long grass, writes Reflector.
Pharmaceutical Executive: Mar 15, 2015
Congress, Obama offer strategies to reduce regulatory roadblocks to new breakthroughs.
Mar 11, 2015
In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes PharmExec Editorial Advisory Board member Cliff Kalb.
Mar 11, 2015
Rohit Sood outlines five critical factors for companies entering this blossoming market.
Pharmaceutical Executive: Mar 10, 2015
Pharma jumps on board personal genomics train—at least for test drive—but will journey ultimately help transform treatment or stall out as just another fad?